Thrombocytopenia — a platelet count below 150,000/µL — is one of the most common hematologic abnormalities nurses encounter across every clinical setting. The priority nursing action depends entirely on the cause: in immune thrombocytopenic purpura (ITP) the risk is bleeding; in heparin-induced thrombocytopenia (HIT) the paradoxical risk is thrombosis. Distinguishing these conditions and acting correctly on each is a fundamental nursing competency — and a high-yield NCLEX topic.
| Type | Key distinguishing feature | Priority nursing action |
|---|---|---|
| ITP (immune thrombocytopenic purpura) | Autoimmune platelet destruction; isolated thrombocytopenia; no other cell line abnormality | Bleeding precautions; administer corticosteroids or IVIG as ordered; avoid NSAIDs and IM injections |
| HIT (heparin-induced thrombocytopenia) | Platelet drop 30–50% from baseline 5–10 days after heparin; thrombosis risk (not just bleeding) | STOP all heparin immediately; do NOT transfuse platelets; start non-heparin anticoagulant (argatroban, fondaparinux, or bivalirudin) |
| TTP (thrombotic thrombocytopenic purpura) | ADAMTS13 deficiency; classic pentad: fever, microangiopathic hemolytic anemia, thrombocytopenia, renal failure, neurological symptoms | Prepare for urgent plasma exchange; do NOT transfuse platelets; monitor neurological status closely |
| Drug-induced | Temporal relationship between drug exposure and platelet drop; resolves after discontinuation | Identify and discontinue the offending drug; bleeding precautions; monitor CBC after cessation |
What is thrombocytopenia: platelet count thresholds and bleeding risk
A normal platelet count is 150,000–400,000/µL. Thrombocytopenia is defined as a count below 150,000/µL. However, the clinical significance scales with severity — a patient with a count of 140,000 carries minimal risk, while a count of 8,000 is a hematologic emergency.
| Severity | Platelet count | Bleeding risk and clinical implications |
|---|---|---|
| Mild | 100,000–150,000/µL | Minimal spontaneous bleeding risk; may prolong bleeding time after trauma or surgery; typically requires no intervention |
| Moderate | 50,000–99,000/µL | Increased bleeding with trauma or procedures; avoid invasive procedures without blood product coverage; assess for easy bruising, prolonged bleeding from minor cuts |
| Severe | 20,000–49,000/µL | Significant spontaneous bleeding risk; petechiae, purpura, mucosal bleeding (gums, nose); platelet transfusion considered for procedures |
| Critical | <20,000/µL | High risk for spontaneous intracranial hemorrhage and GI bleeding; prophylactic platelet transfusion indicated in febrile or at-risk patients at <20,000; indicated in stable patients at <10,000 |
The relationship between platelet count and bleeding is not strictly linear. Platelet function matters as much as count — a patient on aspirin with a count of 80,000 may bleed more than a patient not on any antiplatelet agent with a count of 50,000. Always assess both count and function-altering medications. For a complete reference on normal hematologic lab ranges, see the nursing lab values cheat sheet.
Thrombocytopenia can result from three fundamental mechanisms: decreased production (bone marrow failure, chemotherapy, aplastic anemia), increased destruction (immune-mediated ITP, HIT, TTP), or sequestration (splenomegaly trapping platelets). Nurses need to recognize the mechanism because it shapes both treatment and nursing priorities.
ITP: immune thrombocytopenic purpura
Pathophysiology
ITP is an autoimmune condition in which the immune system produces IgG antibodies against platelet surface antigens — most commonly glycoproteins IIb/IIIa and Ib/IX. These antibody-coated platelets are recognized by Fcγ receptors on splenic macrophages and destroyed by phagocytosis. The spleen is the primary site of both antibody production and platelet destruction, which explains why splenectomy is an effective second-line treatment.
Despite the accelerated platelet destruction, the bone marrow attempts to compensate by increasing platelet production, which is why the peripheral blood smear in ITP shows large (megathrombocytes) or giant platelets — young platelets released prematurely into circulation.
Acute vs. chronic ITP
| Feature | Acute ITP | Chronic ITP |
|---|---|---|
| Typical population | Children ages 2–6 | Adults (any age); female predominance |
| Preceding event | Viral illness 2–4 weeks prior (URI, varicella, EBV, CMV) | Usually insidious; no clear precipitant |
| Duration | <12 months; often resolves in 4–6 weeks | >12 months; typically requires ongoing management |
| Spontaneous resolution | ~80% resolve without treatment | Unlikely without intervention |
| Treatment approach | Watchful waiting if count >30,000 and no significant bleeding; corticosteroids or IVIG if severe or bleeding | Corticosteroids first-line; escalate to splenectomy or TPO agonists for refractory disease |
Diagnosis
ITP is a diagnosis of exclusion. There is no single confirmatory test. The CBC shows isolated thrombocytopenia — WBC and RBC morphology are normal (unlike TTP, where the peripheral smear shows schistocytes and microangiopathic changes). The peripheral blood smear shows large platelets without other abnormalities. Bone marrow biopsy is reserved for atypical cases and shows normal or increased megakaryocytes (the cells that produce platelets — they are compensating), which confirms the problem is destruction, not underproduction.
The workup focuses on excluding secondary causes: HIV and hepatitis C (which can both cause immune thrombocytopenia), lupus (antinuclear antibody panel), drug exposure, and H. pylori infection (eradication can improve platelet counts in H. pylori-positive ITP).
Treatment
| Treatment | Mechanism | Onset | Nursing considerations |
|---|---|---|---|
| Corticosteroids (prednisone 1 mg/kg/day) | Suppress autoantibody production; reduce phagocytosis of antibody-coated platelets | Days to weeks | Monitor blood glucose (hyperglycemia); assess for GI upset; patient education on not stopping abruptly; administer with food |
| IVIG (intravenous immunoglobulin) | Saturates Fc receptors on splenic macrophages, temporarily blocking platelet destruction | 24–72 hours (rapid response) | Infusion reaction risk (headache, fever, chills) — premedicate per protocol; monitor vital signs; used pre-operatively or in emergency bleeding situations |
| Splenectomy | Removes primary site of platelet destruction and antibody production | Days post-op; response in ~70% of patients | Pre-op: administer pneumococcal, meningococcal, and Hib vaccines at least 2 weeks before; post-op: lifelong infection risk from encapsulated bacteria; educate patient to seek care promptly with fever |
| Eltrombopag (oral TPO receptor agonist) | Stimulates thrombopoietin receptor to increase platelet production in bone marrow | 1–2 weeks | Monitor CBC weekly initially; hepatotoxicity monitoring (LFTs); take on empty stomach; used for refractory chronic ITP |
| Romiplostim (SQ injection TPO receptor agonist) | Stimulates thrombopoietin receptor; mimics endogenous TPO | 1–2 weeks | Weekly CBC monitoring; subcutaneous injection (often self-administered); bone marrow fibrosis risk with long-term use |
Key nursing priorities in ITP: Apply bleeding precautions — padded side rails, soft toothbrush, electric razor, avoid IM injections and arterial punctures. Hold NSAIDs, aspirin, and anticoagulants. Educate the patient on signs of dangerous bleeding: sudden severe headache (intracranial hemorrhage), hematuria, melena, or sudden change in mental status. For related anemia management from chronic blood loss, see the anemia nursing reference.
HIT: heparin-induced thrombocytopenia
HIT is the most critical thrombocytopenia concept for nurses to master. It is high-yield on NCLEX for one reason: the management is counter-intuitive. A patient receiving heparin develops a falling platelet count — the instinct is to worry about bleeding and perhaps transfuse platelets. That instinct will harm the patient. HIT causes thrombosis, and giving platelets adds fuel to the fire.
HIT type 1 vs. type 2
| Feature | HIT type 1 (non-immune) | HIT type 2 (immune-mediated) |
|---|---|---|
| Mechanism | Direct platelet activation by heparin (non-immune); transient, self-limiting | IgG antibodies against PF4-heparin complex → platelet activation → thrombosis |
| Onset after heparin | Within 1–4 days | 5–10 days (or <1 day if prior heparin exposure within 100 days) |
| Platelet nadir | Mild drop; rarely <100,000/µL | 30–50% drop from baseline; median nadir ~60,000/µL |
| Thrombosis risk | None | High — both venous and arterial thrombosis |
| Action required | Monitor; heparin can usually continue | Stop ALL heparin immediately; switch to non-heparin anticoagulant; DO NOT give platelets |
| Clinical significance | Benign, resolves spontaneously | Medical emergency — mortality up to 20–30% if not promptly recognized and treated |
When clinicians and nurses refer to “HIT” in clinical practice, they almost always mean HIT type 2 — the immune-mediated, potentially life-threatening form. The remainder of this section addresses HIT type 2 exclusively.
Pathophysiology of HIT type 2
Heparin binds to platelet factor 4 (PF4), a protein released from platelet alpha granules. This heparin-PF4 complex is recognized as foreign by the immune system, which generates IgG antibodies against it. These antibodies bind to heparin-PF4 complexes still attached to platelets, and the Fc portion of the IgG antibody engages FcγRIIa receptors on the platelet surface. This engagement activates the platelets — they aggregate, release more PF4 (creating a positive feedback loop), and generate thrombin. The result is a prothrombotic state with platelet consumption (hence the falling count) and a sharply elevated risk of both venous and arterial thrombosis.
The most common thrombotic complications are DVT and PE, but arterial thrombosis can cause limb ischemia (white clot syndrome), stroke, and myocardial infarction. For the nursing management of DVT as a complication of HIT, see DVT nursing. Pulmonary complications are reviewed in pulmonary embolism nursing.
The 4Ts scoring system
The 4Ts score is the clinical pre-test probability tool for HIT. A score of 0–3 indicates low probability, 4–5 intermediate probability, and 6–8 high probability. In low-probability patients, the negative predictive value is high enough to continue heparin while awaiting lab confirmation. Intermediate and high-probability patients should have heparin stopped and a non-heparin anticoagulant started immediately, before laboratory results return.
| Parameter | 2 points | 1 point | 0 points |
|---|---|---|---|
| Thrombocytopenia (degree of fall) | >50% fall from baseline, nadir ≥20,000/µL | 30–50% fall, or nadir 10,000–19,000/µL | <30% fall, or nadir <10,000/µL |
| Timing of platelet fall | Clear onset day 5–10, or ≤1 day with prior heparin within 100 days | Consistent with day 5–10 onset but unclear (e.g., missing counts); or >10 days onset; or ≤1 day with prior heparin 30–100 days ago | ≤4 days onset without prior heparin exposure |
| Thrombosis or other sequelae | New confirmed thrombosis; skin necrosis at heparin injection sites; acute systemic reaction after IV heparin bolus | Progressive or recurrent thrombosis while on heparin; erythematous skin lesions at injection sites; suspected thrombosis (not yet confirmed) | None |
| Other causes of thrombocytopenia | No other explanation evident | Possible other cause (e.g., sepsis, recent surgery) | Definite other cause present (e.g., post-cardiac bypass nadir, drug with clear temporal relationship) |
Score interpretation: 0–3 = low probability (HIT unlikely; consider other causes); 4–5 = intermediate probability (stop heparin, start non-heparin anticoagulant, send confirmatory labs); 6–8 = high probability (HIT very likely; immediate action required).
Counter-intuitive management: the three rules of HIT
| Rule | Action | Rationale |
|---|---|---|
| Rule 1: Stop ALL heparin | Discontinue IV unfractionated heparin, subcutaneous heparin, heparin flushes, heparin-bonded catheters, and heparin-coated devices immediately | Every source of heparin sustains PF4-heparin complex formation and perpetuates the prothrombotic cycle. Partial discontinuation is not sufficient. |
| Rule 2: Do NOT give platelets | Platelet transfusion is contraindicated in HIT (unless severe life-threatening bleeding) | Transfused platelets provide additional targets for PF4-heparin-IgG activation. Giving platelets to a patient with HIT adds substrate for further thrombosis — the expression "pouring fuel on a fire" is apt. |
| Rule 3: Start a non-heparin anticoagulant | Initiate argatroban, fondaparinux, or bivalirudin immediately — do not wait for laboratory confirmation in intermediate or high-probability cases | The patient remains at high thrombosis risk even after heparin is stopped, because activated platelet aggregates and circulating thrombin persist. Anticoagulation bridges this window. |
Do NOT switch to LMWH (low molecular weight heparin): Enoxaparin and other LMWHs cross-react with the HIT antibodies and will perpetuate the syndrome. This is a common error.
Do NOT start warfarin acutely in HIT: Warfarin depletes protein C (a natural anticoagulant) faster than it depletes the vitamin K–dependent clotting factors, creating a brief hypercoagulable state. In HIT patients, this can cause warfarin-induced skin necrosis and venous limb gangrene. Warfarin can only be introduced after the platelet count has recovered to ≥150,000/µL and the patient has received therapeutic parenteral anticoagulation for at least 5 days.
Non-heparin anticoagulants used in HIT
| Drug | Class | Route | Metabolism | Key nursing points |
|---|---|---|---|---|
| Argatroban | Direct thrombin inhibitor | IV infusion | Hepatic (preferred in renal failure; use caution in liver disease) | Monitor aPTT q2h during dose adjustment; goal aPTT 1.5–3× baseline; affects PT/INR (complicates warfarin transition — use chromogenic factor X assay instead) |
| Bivalirudin | Direct thrombin inhibitor | IV infusion | Enzymatic cleavage and renal (>80%) | Monitor aPTT; reduce dose in renal impairment; short half-life useful in procedures requiring rapid reversal |
| Fondaparinux | Factor Xa inhibitor (synthetic pentasaccharide) | Subcutaneous | Renal (contraindicated if CrCl <30 mL/min) | Does not cross-react with HIT antibodies; no reliable reversal agent (protamine is ineffective); monitor renal function |
Nursing priorities in HIT
The nursing role in HIT extends well beyond administering the ordered anticoagulant. Nurses must:
-
Audit all heparin sources. IV heparin infusions are obvious, but subcutaneous prophylactic heparin, heparin flushes used to maintain IV line patency, heparin-bonded central venous catheters, and heparin-coated pulmonary artery catheters all represent exposure. Eliminate every source.
-
Monitor for thrombosis. HIT-associated thrombosis can manifest as DVT (leg pain, swelling, erythema), PE (sudden dyspnea, pleuritic chest pain, tachycardia, hypoxia), limb ischemia (cool, pulseless, mottled extremity — white clot syndrome), stroke (neurological deficit), or MI (chest pain, EKG changes). Perform systematic assessments at least every shift.
-
Do not perform routine platelet transfusions. Document the contraindication clearly. If a provider orders platelets without apparent awareness of HIT, verify the order and clarify the indication before administering.
-
Document and communicate. HIT status must be visible in the patient record. Future encounters with heparin — even years later — risk reactivation of HIT antibodies. Patients should receive a MedAlert bracelet and written documentation of their heparin allergy/HIT diagnosis at discharge.
-
Monitor anticoagulation levels. Argatroban and bivalirudin require serial aPTT monitoring. Notify the provider if aPTT is outside the therapeutic range or if the patient shows signs of bleeding.
For sepsis-related thrombocytopenia (which can co-occur with HIT and must be distinguished), see sepsis nursing. For overlap with DIC in critically ill patients, see the DIC nursing reference.
TTP and HUS: thrombotic microangiopathies
Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are both thrombotic microangiopathies — conditions in which microthrombi form throughout the small vessel circulation, consuming platelets and mechanically destroying red blood cells. Distinguishing them is clinically important because their treatments differ significantly.
TTP: ADAMTS13 deficiency
Pathophysiology: ADAMTS13 is a plasma metalloprotease that normally cleaves ultra-large von Willebrand factor (vWF) multimers released from endothelial cells. In TTP, ADAMTS13 is deficient — either from acquired autoantibodies (most common in adults) or from hereditary mutation (Upshaw-Schulman syndrome). Without ADAMTS13, uncleaved ultra-large vWF multimers accumulate in the bloodstream and spontaneously bind platelets, forming microthrombi throughout the microcirculation. These microthrombi consume platelets (thrombocytopenia) and shear red blood cells as they try to squeeze through narrowed vessels (microangiopathic hemolytic anemia with schistocytes).
Classic pentad — FAT RN mnemonic:
| Letter | Feature | Clinical presentation |
|---|---|---|
| F | Fever | Low-grade to moderate fever; often present but may be absent |
| A | Anemia (microangiopathic hemolytic) | Pallor, fatigue, jaundice, elevated LDH, elevated indirect bilirubin, schistocytes on peripheral smear, low or absent haptoglobin |
| T | Thrombocytopenia | Often severe (<20,000/µL); petechiae, purpura; paradoxically — spontaneous bleeding risk less prominent than thrombosis risk |
| R | Renal failure | Rising creatinine, oliguria; usually less severe in TTP than HUS; microthrombi in renal glomerular capillaries |
| N | Neurological symptoms | Fluctuating confusion, headache, focal neurological deficits, seizures, coma — hallmark feature distinguishing TTP from HUS; results from microthrombi in cerebral microcirculation |
Not all five features need to be present for diagnosis — the combination of microangiopathic hemolytic anemia and thrombocytopenia with no other clear cause is sufficient to initiate treatment empirically. ADAMTS13 activity level <10% confirms the diagnosis.
Treatment: Plasma exchange (plasmapheresis) is life-saving in TTP. It simultaneously removes the inhibitory ADAMTS13 autoantibodies and replenishes functional ADAMTS13. Without plasma exchange, mortality exceeds 90%. With prompt treatment, survival rates exceed 80%. Do NOT give platelet transfusions — transfused platelets are immediately consumed by the uncleaved vWF multimers, fueling further microthrombus formation.
HUS: hemolytic uremic syndrome
HUS shares the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure with TTP, but differs in several key ways:
| Feature | TTP | HUS (typical, Shiga toxin–associated) |
|---|---|---|
| Primary etiology | ADAMTS13 deficiency (autoantibody or hereditary) | Shiga toxin from E. coli O157:H7 (or Shigella dysenteriae); enters bloodstream from GI tract |
| Typical population | Adults; female predominance | Children; associated with bloody diarrheal illness (hamburger disease) |
| Prodrome | Often no GI prodrome | Bloody diarrhea 5–10 days before renal failure onset |
| Neurological symptoms | Prominent (fluctuating, characteristic) | Less common; predominantly renal involvement |
| Renal failure | Present; usually less severe | Often severe; acute dialysis may be required |
| ADAMTS13 level | <10% (diagnostic) | Normal or mildly reduced |
| Treatment | Plasma exchange (urgent) | Supportive care (fluids, dialysis if needed); antibiotics controversial — may increase toxin release |
| Platelet transfusion | Contraindicated | Generally avoided; use only for life-threatening bleeding |
For the anemia component of TTP and HUS, including interpretation of schistocytes on peripheral smear and the role of LDH and haptoglobin in hemolytic anemia, see the anemia nursing reference.
Drug-induced thrombocytopenia
Drug-induced thrombocytopenia (DITP) occurs when a medication causes platelet destruction, either by triggering an immune response (immune DITP) or by directly suppressing platelet production in the bone marrow (non-immune, myelosuppressive DITP). The key diagnostic clue is a temporal relationship: platelet count falls after drug initiation and recovers after discontinuation.
| Drug | Mechanism | Notes |
|---|---|---|
| Heparin (all forms) | Immune (HIT type 2) — PF4-heparin IgG antibody complex | See HIT section above — requires specific management protocol; platelet transfusion contraindicated |
| Quinine / quinidine | Immune — drug-dependent antibody binds platelet glycoproteins (GPIb/IX and GPIIb/IIIa) | Classic cause; even tonic water (quinine) can precipitate; onset days to weeks; avoid all quinine-containing products |
| GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) | Immune — conformational change in GPIIb/IIIa exposes neo-epitope recognized by natural antibodies | Acute thrombocytopenia within hours of administration; severity can be profound (<20,000); used in PCI and ACS |
| Vancomycin | Immune — drug-dependent antibody formation | Occurs with repeated exposure; monitor CBC in patients on prolonged vancomycin therapy |
| Linezolid | Direct myelosuppression (bone marrow) — inhibits mitochondrial protein synthesis in megakaryocytes | Dose- and duration-dependent; CBC monitoring weekly for courses >2 weeks; reversible upon discontinuation |
| Valproic acid | Dose-dependent myelosuppression; may also be immune-mediated | Common at therapeutic doses; monitor CBC in patients on valproate; dose reduction often sufficient without full discontinuation |
| Chemotherapy agents (carboplatin, gemcitabine, oxaliplatin) | Direct myelosuppression — damage to megakaryocyte precursors in bone marrow | Predictable nadir 10–14 days post-cycle; growth factor support and transfusion thresholds guide management |
| Sulfonamides (trimethoprim-sulfamethoxazole) | Immune — drug-dependent antibody | Monitor CBC; particularly relevant in immunocompromised patients on prophylactic TMP-SMX |
Management of drug-induced thrombocytopenia: Identify and discontinue the offending agent. In immune DITP, the platelet count typically recovers within 5–7 days after drug cessation. In myelosuppressive DITP, recovery depends on bone marrow rebound and may take 2–4 weeks. During the recovery period, apply bleeding precautions and monitor counts serially. Platelet transfusion is reserved for active life-threatening bleeding or for counts below transfusion thresholds in high-risk patients.
Platelet transfusion triggers
Platelet transfusion thresholds are evidence-based guidelines, not absolute rules. Clinical context — active bleeding, procedural risk, platelet function impairment, and the underlying cause of thrombocytopenia — always modifies the threshold.
| Clinical situation | Platelet threshold for transfusion | Rationale |
|---|---|---|
| Stable, non-bleeding patient (prophylactic) | <10,000/µL | Below this threshold, spontaneous intracranial hemorrhage risk rises substantially; prophylactic transfusion prevents catastrophic bleeding |
| Febrile patient or patient with additional bleeding risk factors | <20,000/µL | Fever independently increases bleeding risk; active infection, coagulopathy, or antiplatelet drugs lower the threshold to <20,000 |
| Invasive procedures (central line, bronchoscopy, lumbar puncture) | <50,000/µL | Most invasive procedures carry acceptable procedural bleeding risk at counts ≥50,000; confirm specific thresholds with proceduralist |
| Major surgery (non-neurological) | <50,000/µL | Surgical hemostasis requires adequate platelet count and function; some surgeons prefer >80,000 for higher-risk procedures |
| Neurosurgery or spinal procedures | <100,000/µL | Intracranial and spinal bleeding is poorly tolerated; higher threshold required |
| Active, life-threatening hemorrhage | Regardless of count; target >50,000 (or >100,000 in CNS bleeding) | Massive hemorrhage protocol often specifies empiric platelet transfusion regardless of measured count |
| HIT, TTP, or immune-mediated thrombocytopenia | Transfusion contraindicated except for life-threatening bleeding | Transfused platelets are consumed and worsen thrombosis in these conditions |
One unit of platelet concentrate (apheresis single-donor unit) is expected to raise the platelet count by 30,000–60,000/µL in an average adult. A one-hour post-transfusion CBC confirms the corrected count increment. Poor response (inadequate increment) may indicate platelet refractoriness from HLA alloimmunization, requiring HLA-matched platelets.
Nursing assessment and monitoring for thrombocytopenia
Thorough physical assessment is the foundation of thrombocytopenia nursing. The goal is to detect bleeding early — before it becomes life-threatening — and to identify signs of end-organ compromise from thrombosis in conditions like HIT and TTP.
Skin and mucosal bleeding assessment:
- Petechiae: Pinpoint (1–3 mm) reddish-purple spots caused by red blood cells leaking through capillaries into skin; do not blanch with pressure; classic sign of severe thrombocytopenia; often appear first on dependent areas, ankles, and buccal mucosa
- Purpura: Larger (3–10 mm) areas of skin hemorrhage; non-blanchable; may coalesce into ecchymoses
- Ecchymoses: Bruising; assess for spontaneous bruising in unusual locations (not from known trauma)
- Mucosal bleeding: Bleeding gums (gingivorrhagia), prolonged epistaxis, blood blisters on buccal mucosa (wet purpura — indicates severe thrombocytopenia and risk for intracranial bleeding)
Internal bleeding assessment:
- Neurological: sudden severe headache (intracranial hemorrhage), altered mental status, focal neurological deficits, pupillary changes — perform neurological checks every 4 hours or per protocol
- GI: hematemesis, melena (black tarry stool), hematochezia (bright red blood per rectum), abdominal pain or distension; measure all emesis and stool for occult blood
- Genitourinary: hematuria (pink, red, or cola-colored urine); measure urine output and document color
- Retroperitoneal: flank pain, abdominal pain radiating to the back, hemodynamic instability without obvious source
Thrombosis assessment (HIT, TTP):
- Extremities: asymmetric leg swelling, erythema, warmth, pain — DVT; compare bilateral calf circumference
- Respiratory: new dyspnea, pleuritic chest pain, tachypnea, hypoxia — PE; monitor oxygen saturation continuously
- Neurological: fluctuating confusion, focal deficits — cerebral thrombosis (particularly in TTP)
- Peripheral vascular: cool, pale, or mottled extremity; diminished or absent pulses — arterial thrombosis / white clot syndrome (HIT)
For a systematic head-to-toe assessment framework applicable to all hematologic patients, see the head-to-toe assessment guide.
Nursing diagnoses for thrombocytopenia
| Nursing diagnosis | Related to | Evidenced by | Priority interventions |
|---|---|---|---|
| Risk for bleeding | Decreased platelet count secondary to [ITP / HIT / drug-induced / TTP] | Platelet count <50,000/µL; presence of petechiae or purpura; mucosal bleeding | Bleeding precautions (soft toothbrush, electric razor, padded rails); avoid IM injections; apply prolonged pressure to venipuncture sites; hold NSAIDs and anticoagulants as ordered; fall prevention |
| Risk for ineffective peripheral tissue perfusion | Microthrombus formation in peripheral vasculature (HIT type 2, TTP) | Platelet count falling with heparin exposure; extremity pain, pallor, or pulselessness; elevated D-dimer | Perform neurovascular checks of all extremities q4h; palpate and document peripheral pulses; report any new asymmetry, pallor, or pain promptly; ensure non-heparin anticoagulant is initiated |
| Deficient knowledge | Unfamiliarity with diagnosis, bleeding precautions, and long-term implications | Patient questions about heparin avoidance; lack of understanding of HIT implications for future care; inability to verbalize bleeding warning signs | Teach signs of serious bleeding requiring emergency care; instruct on heparin avoidance (HIT) and MedAlert bracelet; review home medications (NSAIDs, antiplatelet agents) for safety; provide written discharge instructions |
| Anxiety | Uncertain diagnosis, complex treatment plan, fear of complications | Patient and family verbalize worry; increased questioning; physical signs of anxiety (tachycardia, restlessness) | Explain diagnosis and management plan in plain language; involve patient in care decisions; provide consistent nursing contact; liaise with social work or chaplaincy as appropriate |
| Risk for injury (falls) | Thrombocytopenia combined with dizziness from anemia or altered perfusion | Platelet count <50,000; hemoglobin low from concurrent hemolytic anemia; orthostatic hypotension present | Bed alarm on; non-slip footwear; call light within reach; assist with ambulation; orthostatic vital signs before out-of-bed activities |
| Impaired gas exchange | PE secondary to HIT-associated venous thromboembolism | New dyspnea, hypoxia (SpO2 <94%), tachycardia, pleuritic chest pain | Administer supplemental oxygen; position patient with HOB elevated; continuous pulse oximetry; notify provider; prepare for imaging (CT pulmonary angiography); ensure non-heparin anticoagulation is in progress |
NCLEX-style practice questions
Question 1
A patient has been receiving IV heparin for DVT treatment for 7 days. The morning CBC shows platelets of 68,000/µL, down from a baseline of 220,000/µL on admission. The patient’s 4Ts score is calculated at 6. Which nursing action is the highest priority?
A) Prepare to administer a platelet transfusion to prevent bleeding complications. B) Notify the provider, anticipate discontinuation of all heparin, and prepare to initiate a non-heparin anticoagulant. C) Reduce the heparin infusion rate by 50% and repeat the platelet count in 4 hours. D) Switch the patient from unfractionated heparin to enoxaparin (LMWH) as ordered.
Reveal answer and rationale
Correct answer: B
A 4Ts score of 6 indicates high probability of HIT type 2. The appropriate response is to stop ALL heparin immediately, notify the provider, and initiate a non-heparin anticoagulant (argatroban, fondaparinux, or bivalirudin). HIT is a prothrombotic condition — the risk is thrombosis, not bleeding.
Why A is wrong: Platelet transfusion is contraindicated in HIT. Transfused platelets provide additional substrate for antibody-mediated platelet activation, worsening the thrombotic risk.
Why C is wrong: Reducing the heparin rate does not address the underlying immunological mechanism. Continued heparin exposure — even at lower doses — perpetuates HIT.
Why D is wrong: LMWH (enoxaparin) cross-reacts with HIT antibodies and cannot be used as a substitute. Switching to LMWH would perpetuate the condition.
Question 2
A 6-year-old child presents with bruising, petechiae, and a platelet count of 18,000/µL. The CBC shows isolated thrombocytopenia with normal WBC and RBC morphology. The peripheral smear shows large platelets with no schistocytes. The parents report the child had a “stomach bug” about 3 weeks ago. Which diagnosis and management approach is most consistent with these findings?
A) HIT type 2 — stop all heparin and start argatroban B) TTP — initiate urgent plasma exchange C) Acute ITP — observe or treat with corticosteroids or IVIG depending on severity; most cases resolve spontaneously D) Drug-induced thrombocytopenia — identify and discontinue the offending medication
Reveal answer and rationale
Correct answer: C
The presentation is classic for acute ITP in a child: isolated thrombocytopenia, large platelets on smear, no schistocytes (ruling out TTP/HUS), preceding viral illness 2–4 weeks prior. Approximately 80% of acute pediatric ITP cases resolve spontaneously within weeks to months. For a count of 18,000 without active bleeding, management may be observation alone or corticosteroids/IVIG if the clinical team determines treatment is warranted.
Why A is wrong: HIT requires heparin exposure. There is no heparin exposure in this pediatric case.
Why B is wrong: TTP features schistocytes (shredded RBCs) on peripheral smear, microangiopathic hemolytic anemia, and often neurological symptoms. The smear here is normal except for large platelets.
Why D is wrong: Nothing in the history suggests drug exposure as the cause. The post-viral context strongly supports ITP.
Question 3
A patient with chronic ITP is scheduled for a laparoscopic cholecystectomy in two weeks. Current platelet count is 42,000/µL. Which intervention does the nurse anticipate will most likely be ordered to rapidly raise the platelet count before surgery?
A) Oral prednisone 1 mg/kg/day for 2 weeks B) IVIG infusion 1–2 days pre-operatively C) Splenectomy performed at the same time as cholecystectomy D) Prophylactic platelet transfusion the morning of surgery
Reveal answer and rationale
Correct answer: B
IVIG provides the most rapid platelet response (within 24–72 hours) among available ITP treatments, making it the preferred option when a quick rise in count is needed before a scheduled procedure. It works by saturating Fc receptors on splenic macrophages, temporarily halting antibody-mediated platelet destruction.
Why A is wrong: Corticosteroids can raise platelet counts in ITP but take days to weeks to reach peak effect — too slow to reliably achieve a safe count in 1–2 days pre-operatively. Corticosteroids may be added alongside IVIG for an additive effect.
Why C is wrong: Splenectomy is a second-line treatment for refractory chronic ITP — it is not performed as an incidental procedure during unrelated surgery without significant deliberation and pre-operative vaccination.
Why D is wrong: Platelet transfusion in ITP provides only transient benefit because transfused platelets are destroyed by the same autoantibody mechanism as native platelets. Transfusion is reserved for emergency bleeding, not pre-operative prophylaxis when time allows for ITP-specific treatment.
Question 4
A patient with severe thrombocytopenia, microangiopathic hemolytic anemia, and a creatinine of 3.2 mg/dL develops sudden confusion and reports a severe headache. Lab results show ADAMTS13 activity at 5%. Which treatment does the nurse prepare to assist with?
A) Platelet transfusion to correct the count before any procedures B) Plasma exchange (plasmapheresis) C) Initiation of IV heparin anticoagulation D) Administration of fresh frozen plasma (FFP) only, without plasma exchange
Reveal answer and rationale
Correct answer: B
The presentation describes TTP: microangiopathic hemolytic anemia + thrombocytopenia + renal failure + neurological symptoms, confirmed by ADAMTS13 activity <10%. Plasma exchange is the definitive, life-saving treatment. It removes the autoantibodies against ADAMTS13 and replaces functional ADAMTS13 via fresh frozen plasma as the exchange fluid. Without urgent plasma exchange, mortality exceeds 90%.
Why A is wrong: Platelet transfusion in TTP is contraindicated. Transfused platelets are incorporated into the pathological microthrombi, worsening organ ischemia.
Why C is wrong: Heparin is not indicated in TTP. The mechanism is vWF-mediated platelet aggregation, not the typical coagulation cascade. Heparin would also create additional bleeding risk.
Why D is wrong: FFP infusion alone (without exchange) does replace some ADAMTS13 but cannot remove the autoantibodies driving the process. The volume required to meaningfully replace ADAMTS13 via infusion alone would cause fluid overload. Plasma exchange is required.
Question 5
A stable patient with chemotherapy-induced thrombocytopenia has a platelet count of 14,000/µL. She has no active bleeding and no fever. Which nursing action is most appropriate?
A) Administer a platelet transfusion per the standing protocol for counts <20,000 B) Continue to monitor; a platelet transfusion is only indicated if the count falls below 10,000/µL in a stable, non-bleeding patient C) Place the patient in strict isolation to prevent platelet loss from infection D) Administer IVIG to stimulate platelet production
Reveal answer and rationale
Correct answer: B
In a stable, non-bleeding, afebrile patient, current evidence-based guidelines support a prophylactic transfusion threshold of <10,000/µL. A count of 14,000 in a stable patient does not yet meet the threshold. Nursing management at this level includes bleeding precautions, fall prevention, activity restriction, and close monitoring.
Why A is wrong: The <20,000 threshold applies to febrile or at-risk patients. This patient is stable and afebrile; the correct threshold in this context is <10,000.
Why C is wrong: Isolation is not indicated for thrombocytopenia. Isolation protocols apply to neutropenia (infection risk). Thrombocytopenia creates bleeding risk, not infection risk — though the two can coexist in chemotherapy patients, isolation is ordered based on neutrophil count, not platelet count.
Why D is wrong: IVIG is a treatment for ITP (immune-mediated platelet destruction), not for chemotherapy-induced myelosuppression. IVIG does not stimulate platelet production.
Question 6
A patient receiving argatroban for confirmed HIT has a stable platelet count of 60,000/µL after 3 days of therapy. The medical team plans to transition to oral warfarin. Which nursing concern should be communicated to the prescriber before warfarin is initiated?
A) The patient’s platelet count must be ≥150,000/µL before warfarin can be safely initiated B) Warfarin should be started now because the patient’s platelet count is trending upward C) Warfarin is contraindicated in all patients with a prior HIT diagnosis and should never be used D) Argatroban can be discontinued immediately once the first dose of warfarin is given
Reveal answer and rationale
Correct answer: A
Warfarin is not safe to initiate in HIT until the platelet count has recovered to at least 150,000/µL. In active HIT, warfarin depletes protein C (a natural anticoagulant) faster than the procoagulant factors, creating a transient hypercoagulable state that can cause warfarin-induced skin necrosis and venous limb gangrene. With a count of 60,000, the patient’s HIT is not yet fully resolved. Additionally, the parenteral anticoagulant (argatroban) must overlap with warfarin for at least 5 days before discontinuation, and the INR target must account for argatroban’s effect on the PT/INR.
Why B is wrong: A rising count of 60,000 indicates recovery is underway but is not sufficient for safe warfarin initiation. The threshold is 150,000/µL, not simply “trending upward.”
Why C is wrong: Warfarin is not permanently contraindicated after HIT — it is contraindicated only during the acute thrombocytopenic phase. Many patients with a history of HIT are eventually transitioned to warfarin for long-term anticoagulation once platelet counts fully recover.
Why D is wrong: Abrupt discontinuation of argatroban when warfarin is started would leave the patient unprotected during the period before warfarin reaches therapeutic anticoagulant effect. Overlap for ≥5 days with a therapeutic INR (accounting for argatroban’s PT elevation) is required.
Summary
Thrombocytopenia requires nurses to think diagnostically, not just respond to the number on the lab report. The cause determines everything. ITP calls for bleeding precautions and immune-modulating therapy. HIT demands immediate cessation of all heparin, contraindication of platelet transfusion, and prompt initiation of a non-heparin anticoagulant — the counter-intuitive management of a condition driven by thrombosis, not bleeding. TTP requires urgent plasma exchange and the same platelet transfusion contraindication. Drug-induced thrombocytopenia resolves when the offending agent is removed.
Platelet transfusion thresholds provide an evidence-based framework for prophylaxis: <10,000 in stable patients, <20,000 in febrile or at-risk patients, <50,000 for most procedures, and <100,000 for neurosurgical intervention. In HIT and TTP, those thresholds are irrelevant — transfusion is contraindicated regardless of count.
For the broader hematologic context, including the coagulation cascade dysfunction that can accompany critical thrombocytopenia, review the DIC nursing reference. For nursing management of sickle cell disease — another condition in which platelet and RBC dysfunction coexist — see sickle cell disease nursing.